{"title": "Tratamiento farmacol\u00f3gico para COVID-19 en protocolos latinoamericanos: Una revisi\u00f3n narrativa de la eficacia y seguridad", "author": "Pamela Alejandra Escalante Saavedra; Mart\u00edn Ca\u00f1\u00e1s; Dulce Mar\u00eda Calvo Barbado; Liliana Barajas Esparza; Mariana Caffaratti; Noelia Speranza; Carlos Fuentes Mart\u00ednez; Jos\u00e9 Juli\u00e1n L\u00f3pez Guiti\u00e9rrez", "url": null, "hostname": null, "description": "Introduction: The pandemic caused by SARS-CoV-2 has put the global scientific community in an accelerated pace of research for an effective treatment for COVID-19. Objective: To identify and evaluate drugs in Latin American protocols of pharmacological treatment for COVID-19. Method: The evidence and mega trial results available to date on the most frequent medications are analyzed. Results: The most common drugs in national protocols are hydroxychloroquine, lopinavir/ritonavir, and remdesivir. None of the drugs that collect the most data from clinical studies, with the except for dexamethasone in a small subgroup of patients, so far showed significant differences in mortality. Conclusions: The emerging situation of COVID-19 has determined hasty and controversial decision-making based on questionable and/or low-quality studies. This highlights the provisional nature of the information and the possibility of generating changes as more results become available. Advance medication authorization exposes a known problem. Although regulatory agility is required at this time, speed should not overlap with basic ethical standards and trust in evidence.", "sitename": "Vigil Sanit Debate, Rio de Janeiro", "date": "2020-08-14", "id": null, "license": "CC BY 3.0", "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Tratamiento farmacol\u00f3gico para COVID-19 en protocolos latinoamericanos: Una revisi\u00f3n narrativa de la eficacia y seguridad\nDOI:\n[https://doi.org/10.22239/2317-269x.01741](https://doi.org/10.22239/2317-269x.01741)\nPalavras-chave:COVID-19; Protocolos Cl\u00ednicos; Medicamentos; Medicina Basada en Evidencia; Latinoam\u00e9rica\nResumo\nT\u00edtulo PT: Tratamento farmacol\u00f3gico para COVID-19 em protocolos Latinoam\u00e9rica: Uma revis\u00e3o narrativa da efic\u00e1cia e da seguran\u00e7a\nIntroducci\u00f3n: La pandemia causada por el SARS-Cov-2 ha puesto a la comunidad cient\u00edfica mundial en ritmo acelerado de investigaci\u00f3n y busca por un tratamiento efectivo para COVID-19. Objetivo: Identificar y evaluar medicamentos en protocolos latinoamericanos de tratamiento farmacol\u00f3gico para el COVID-19. M\u00e9todo: Se analiza la evidencia y resultados de mega ensayo disponibles hasta la fecha sobre los medicamentos m\u00e1s frecuentes. Resultados: Los medicamentos m\u00e1s frecuentes en protocolos nacionales son hidroxicloroquina, lopinavir/ritonavir y remdesivir. Ninguno de los medicamentos que recopilan mayor cantidad de datos provenientes de estudios cl\u00ednicos, a excepci\u00f3n de la dexametasona en un subgrupo reducido de pacientes, mostr\u00f3, hasta el momento, diferencias significativas en la mortalidad. Conclusiones: La situaci\u00f3n emergente de la COVID-19 ha determinado la toma de decisiones apresuradas y controversiales con base en estudios cuestionables y/o de baja calidad. Esto pone de relieve el car\u00e1cter provisorio de la informaci\u00f3n y la posibilidad de generar cambios a medida que se dispongan de m\u00e1s resultados. La autorizaci\u00f3n anticipada de medicamentos expone un problema conocido. A pesar de que la agilidad regulatoria es necesaria en este momento, la velocidad no debe sobreponerse a los patrones b\u00e1sicos \u00e9ticos y de confianza en la evidencia.\nDownloads\nPublicado\nComo Citar\nEdi\u00e7\u00e3o\nSe\u00e7\u00e3o\nLicen\u00e7a\nCopyright (c) 2020 Vigil\u00e2ncia Sanit\u00e1ria em Debate: Sociedade, Ci\u00eancia & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) \u2013 Visa em Debate\nEsta obra est\u00e1 licenciado com uma Licen\u00e7a\n[Creative Commons Attribution 3.0 Unported License](http://creativecommons.org/licenses/by/3.0/).\nTERMO DE CESS\u00c3O DE DIREITOS AUTORAIS O(s) autor(es) doravante designado(s) CEDENTE, por meio desta, cede e transfere, de forma gratuita, a propriedade dos direitos autorais relativos \u00e0 OBRA \u00e0 REVISTA Vigil\u00e2ncia Sanit\u00e1ria em Debate: Sociedade, Ci\u00eancia & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) \u2013 Visa em Debate e, representada por FUNDA\u00c7\u00c3O OSWALDO CRUZ, estabelecida na Av. Brasil, n\u00ba 4365, Manguinhos, Rio de Janeiro, RJ, Brasil, CEP 21045-900, doravante designada CESSION\u00c1RIA, nas condi\u00e7\u00f5es descritas a seguir: 1. O CEDENTE declara que \u00e9 (s\u00e3o) autor(es) e titular(es) da propriedade dos direitos autorais da OBRA submetida. 2. O CEDENTE declara que a OBRA n\u00e3o infringe direitos autorais e/ou outros direitos de propriedade de terceiros, que a divulga\u00e7\u00e3o de imagens (caso as mesmas existam) foi autorizada e que assume integral responsabilidade moral e/ou patrimonial, pelo seu conte\u00fado, perante terceiros. 3. O CEDENTE cede e transfere todos os direitos autorais relativos \u00e0 OBRA \u00e0 CESSION\u00c1RIA, especialmente os direitos de edi\u00e7\u00e3o, de publica\u00e7\u00e3o, de tradu\u00e7\u00e3o para outro idioma e de reprodu\u00e7\u00e3o por qualquer processo ou t\u00e9cnica. A CESSION\u00c1RIA passa a ser propriet\u00e1ria exclusiva dos direitos referentes \u00e0 OBRA, sendo vedada qualquer reprodu\u00e7\u00e3o, total ou parcial, em qualquer outro meio de divulga\u00e7\u00e3o, impresso ou eletr\u00f4nico, sem que haja pr\u00e9via autoriza\u00e7\u00e3o escrita por parte da CESSION\u00c1RIA. 4. A cess\u00e3o \u00e9 gratuita e, portanto, n\u00e3o haver\u00e1 qualquer tipo de remunera\u00e7\u00e3o pela utiliza\u00e7\u00e3o da OBRA pela CESSION\u00c1RIA.", "language": null, "image": null, "pagetype": null, "links": ["#pkp_content_main", "#siteNav", "#pkp_content_footer", "\t\t\t\t\t\thttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/index\n\t\t\t\t\t", null, "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/index", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/about", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/about", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/about/editorialTeam", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/user/register", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/about/submissions", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/info_autores", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/about/privacy", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/issue/view/56", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/issue/archive", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/announcement", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/about/contact", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/search", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/user/register", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/login", null, "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/index", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/issue/archive", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/issue/view/46", "http://orcid.org/0000-0003-0191-4130", "http://orcid.org/0000-0003-0500-5866", "http://orcid.org/0000-0002-1811-9099", "http://orcid.org/0000-0002-4772-612X", "http://orcid.org/0000-0002-6141-2688", "http://orcid.org/0000-0002-3330-9974", "http://orcid.org/0000-0003-2568-8625", "http://orcid.org/0000-0002-5264-6212", "https://doi.org/10.22239/2317-269x.01741", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/issue/view/46", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1741/1216", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1741/1278", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/acm-sig-proceedings?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/acs-nano?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/apa?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/associacao-brasileira-de-normas-tecnicas?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/chicago-author-date?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/harvard-cite-them-right?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/ieee?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/modern-language-association?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/turabian-fullnote-bibliography?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/get/vancouver?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/download/ris?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/citationstylelanguage/download/bibtex?submissionId=1741&publicationId=1077", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/issue/view/46", "http://creativecommons.org/licenses/by/3.0/", "http://creativecommons.org/licenses/by/3.0/", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/about/submissions", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/user/setLocale/en_US?source=%2Findex.php%2Fvisaemdebate%2Farticle%2Fview%2F1741", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/user/setLocale/pt_BR?source=%2Findex.php%2Fvisaemdebate%2Farticle%2Fview%2F1741", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/user/setLocale/es_ES?source=%2Findex.php%2Fvisaemdebate%2Farticle%2Fview%2F1741", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/information/readers", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/information/authors", "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/information/librarians", "https://www.facebook.com/revistavisaemdebate/", "https://www.facebook.com/revistavisaemdebate/", "https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/veiculoPublicacaoQualis/listaConsultaGeralPeriodicos.jsf", "https://scholar.google.com/citations?hl=pt-BR&view_op=list_hcore&venue=bXQ0-UAf8qQJ.2022", "https://www.redalyc.org/revista.oa?id=5705&tipo=coleccion", "http://www.latindex.unam.mx/", "http://www.doaj.org/", "http://mjl.clarivate.com/", "http://www.sumarios.org/", "http://diadorim.ibict.br/handle/1/620/", "https://scholar.google.com.br/", "http://lilacs.bvsalud.org/", "http://oasisbr.ibict.br//", "https://search.crossref.org/?q=2317-269X", "http://www.periodicos.capes.gov.br/", "https://periodicos.fiocruz.br/", "https://www.arca.fiocruz.br/", "https://portal.issn.org/resource/ISSN/2317-269X", "http://pkp.sfu.ca/ojs/", null, "https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/about/aboutThisPublishingSystem"]}